Top

Published in:

Open Access 01-12-2013 | Research article

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls

Authors: Nicholas Willumsen, Cecilie L Bager, Diana J Leeming, Victoria Smith, Morten A Karsdal, David Dornan, Anne-Christine Bay-Jensen

Published in: BMC Cancer | Issue 1/2013

Abstract

Background

Pancreatic cancer (PC) is an aggressive disease with an urgent need for biomarkers. Hallmarks of PC include increased collagen deposition (desmoplasia) and increased matrix metalloproteinase (MMP) activity. The aim of this study was to investigate whether protein fingerprints of specific MMP-generated collagen fragments differentiate PC patients from healthy controls when measured in serum.

Methods

The levels of biomarkers reflecting MMP-mediated degradation of type I (C1M), type III (C3M) and type IV (C4M, C4M12a1) collagen were assessed in serum samples from PC patients (n = 15) and healthy controls (n = 33) using well-characterized and validated competitive ELISAs.

Results

The MMP-generated collagen fragments were significantly elevated in serum from PC patients as compared to controls. The diagnostic power of C1M, C3M, C4M and C4M12 were ≥83% (p < 0.001) and when combining all biomarkers 99% (p < 0.0001).

Conclusions

A panel of serum biomarkers reflecting altered MMP-mediated collagen turnover is able to differentiate PC patients from healthy controls. These markers may increase the understanding of mode of action of the disease and, if validated in larger clinical studies, provide an improved and additional tool in the PC setting.

Available only for authorised users

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30. 10.3322/caac.21166.CrossRefPubMed

Malvezzi M, Bertuccio P, Levi F, La VC, Negri E: European cancer mortality predictions for the year 2013. Ann Oncol. 2013, 24: 792-800. 10.1093/annonc/mdt010.CrossRefPubMed

Olson P, Hanahan D: Cancer. Breaching the cancer fortress. Science. 2009, 324: 1400-1401. 10.1126/science.1175940.CrossRefPubMed

Chu D, Kohlmann W, Adler DG: Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP. 2010, 11: 203-212.PubMed

Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010, 141: 52-67. 10.1016/j.cell.2010.03.015.CrossRefPubMedPubMedCentral

Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC, et al: Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol. 2013, 11: 70-92. 10.1089/adt.2012.474.CrossRefPubMedPubMedCentral

Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG: Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J. 2012, 441: 541-552. 10.1042/BJ20111240.CrossRefPubMed

Sawai H, Okada Y, Funahashi H, Takahashi H, Matsuo Y, Yasuda A, et al: Basement membrane proteins play an important role in the invasive processes of human pancreatic cancer cells. J Surg Res. 2008, 144: 117-123. 10.1016/j.jss.2007.03.023.CrossRefPubMed

Ohlund D, Franklin O, Lundberg E, Lundin C, Sund M: Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer. 2013, 13: 154-10.1186/1471-2407-13-154.CrossRefPubMedPubMedCentral

10.

Karsdal MA, Delvin E, Christiansen C: Protein fingerprints - relying on and understanding the information of serological protein measurements. Clin Biochem. 2011, 44: 1278-1279. 10.1016/j.clinbiochem.2011.08.1135.CrossRefPubMed

11.

Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, et al: A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011, 16: 616-628. 10.3109/1354750X.2011.620628.CrossRefPubMed

12.

Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al: A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010, 43: 899-904. 10.1016/j.clinbiochem.2010.03.012.CrossRefPubMed

13.

Veidal SS, Karsdal MA, Nawrocki A, Larsen MR, Dai Y, Zheng Q, et al: Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair. 2011, 4: 22-10.1186/1755-1536-4-22.CrossRefPubMedPubMedCentral

14.

Sand JM, Larsen L, Hogaboam CM, Martinez FJ, Han M, Larsen MR, et al: MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis – Validation of two novel biomarker assays. PLoS One. 2013, in press

15.

Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009, 139: 891-906. 10.1016/j.cell.2009.10.027.CrossRefPubMedPubMedCentral

16.

Ohlund D, Lundin C, Ardnor B, Oman M, Naredi P, Sund M: Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer. 2009, 101: 91-97. 10.1038/sj.bjc.6605107.CrossRefPubMedPubMedCentral

17.

Nurmenniemi S, Koivula MK, Nyberg P, Tervahartiala T, Sorsa T, Mattila PS, et al: Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. Oral Oncol. 2012, 48: 136-140. 10.1016/j.oraloncology.2011.09.002.CrossRefPubMed

18.

Nicoloff G, Deliiyski T, Nikolov A: Detection of Serum Collagen Type IV and Elastin Derived Peptides in Patients With Breast Cancer. Diabetol Croat. 2010, 39: 81-112.

19.

Mazouni C, Arun B, Andre F, Ayers M, Krishnamurthy S, Wang B, et al: Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer. 2008, 99: 68-71. 10.1038/sj.bjc.6604443.CrossRefPubMedPubMedCentral

20.

Hong WS, Hong SI, Park SY, Son Y, Lee YS, Chung YH, et al: Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis. Anticancer Res. 1995, 15: 2777-2780.PubMed

21.

Nystrom H, Naredi P, Hafstrom L, Sund M: Type IV collagen as a tumour marker for colorectal liver metastases. Eur J Surg Oncol. 2011, 37: 611-617. 10.1016/j.ejso.2011.04.010.CrossRefPubMed

22.

Kubo S, Tsukamoto T, Hirohashi K, Tanaka H, Shuto T, Takemura S, et al: Correlation between preoperative serum concentration of type IV collagen 7 s domain and hepatic failure following resection of hepatocellular carcinoma. Ann Surg. 2004, 239: 186-193. 10.1097/01.sla.0000109152.48425.4d.CrossRefPubMedPubMedCentral

23.

Mason SD, Joyce JA: Proteolytic networks in cancer. Trends Cell Biol. 2011, 21: 228-237. 10.1016/j.tcb.2010.12.002.CrossRefPubMed

24.

Martin MD, Matrisian LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007, 26: 717-724. 10.1007/s10555-007-9089-4.CrossRefPubMed

25.

Zucker S, Cao J: Matrix Metalloproteinases and Cancer Cell Invasion/Metastasis. The tumor microenviroment. Edited by: Bagley RG. 2010, New York: Springer Science+Business Media, LLC, 531-554.CrossRef

26.

Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006, 6: 227-239. 10.1038/nrc1821.CrossRefPubMed

27.

Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, et al: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001, 154: 1069-1079. 10.1083/jcb.200103111.CrossRefPubMedPubMedCentral

28.

Xu J, Rodriguez D, Kim JJ, Brooks PC: Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma. 2000, 19: 375-385. 10.1089/02724570050198893.CrossRefPubMed

29.

Mundel TM, Kalluri R: Type IV collagen-derived angiogenesis inhibitors. Microvasc Res. 2007, 74: 85-89. 10.1016/j.mvr.2007.05.005.CrossRefPubMedPubMedCentral

30.

Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000, 19: 6642-6650. 10.1038/sj.onc.1204097.CrossRefPubMed

31.

Pannala R, Basu A, Petersen GM, Chari ST: New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009, 10: 88-95. 10.1016/S1470-2045(08)70337-1.CrossRefPubMedPubMedCentral

32.

Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, et al: Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol. 2004, 182: 897-903. 10.2214/ajr.182.4.1820897.CrossRefPubMed

33.

Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S: Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004, 28: 38-44. 10.1097/00006676-200401000-00006.CrossRefPubMed

34.

Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK: Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012, 6: 597-612. 10.2217/bmm.12.69.CrossRefPubMedPubMedCentral

35.

Wu E, Zhou S, Bhat K, Ma Q: CA 19–9 and pancreatic cancer. Clin Adv Hematol Oncol. 2013, 11: 53-55.PubMedPubMedCentral

36.

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006, 24: 5313-5327. 10.1200/JCO.2006.08.2644.CrossRefPubMed

37.

Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh TC, et al: Advances in biomarker research for pancreatic cancer. Curr Pharm Des. 2012, 18: 2439-2451. 10.2174/13816128112092439.CrossRefPubMedPubMedCentral

38.

Wingren C, Sandstrom A, Segersvard R, Carlsson A, Andersson R, Lohr M, et al: Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 2012, 72: 2481-2490. 10.1158/0008-5472.CAN-11-2883.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/554/prepub

Title: Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls
Authors: Nicholas Willumsen
Cecilie L Bager
Diana J Leeming
Victoria Smith
Morten A Karsdal
David Dornan
Anne-Christine Bay-Jensen
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-13-554

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells

Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, proteins binding ARTEMIN, in mammary carcinoma

Polycyclic aromatic hydrocarbons: determinants of urinary 1-hydroxypyrene glucuronide concentration and risk of colorectal cancer in the Shanghai Women’s Health Study

Napsin A as a marker of clear cell ovarian carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer